Medtronic Anticipates Turnaround For Challenged Business Units
This article was originally published in The Gray Sheet
Executives focused on new developments in the company’s ICD, spine, neuromodulation, and diabetes product lines, which have each faced particular challenges over the past year, during Medtronic’s second-quarter fiscal 2014 earnings call.
You may also be interested in...
New product approvals and launches announced this week include a new sinus dilation system and cervical disc from Medtronic, an aortic valve with a novel removable stent from Sorin, and a toe-repair device from Smith & Nephew.
Medtronic recently announced FDA approval of its MiniMed 530G low-glucose-suspend insulin pump, the first system approved in the U.S. that can automatically stop insulin delivery when blood glucose levels fall to a pre-set level.
News Briefs: Medtronic’s First-Gen Artificial Pancreas Approved; CMS Removes Bariatric Surgery Requirements
FDA approves Medtronic’s MiniMed 530G system, making it the first system in the U.S. that can automatically suspend insulin delivery to people with diabetes. CMS removes bariatric surgery facility certification requirements. More news.